Amylyx Pharmaceuticals Terminates AMX0035 Program
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) recently announced a significant decision to halt its ORION program for AMX0035, a treatment involving sodium phenylbutyrate and taurursodiol. This decision stems from the drug's lack of efficacy in patients diagnosed with progressive supranuclear palsy (PSP).
Understanding Progressive Supranuclear Palsy
Progressive supranuclear palsy is a rare and challenging degenerative brain disorder. Those affected by PSP typically experience severe issues with balance, movement, speech, swallowing, and cognitive abilities. The impact of such a diagnosis can be devastating for individuals and their families.
The Results of the Trial
In the latest trial, AMX0035 failed to show significant differences when compared to a placebo in both primary and secondary outcomes after 24 weeks of treatment. As a result, the company has decided to discontinue the Phase 2b trial and will not proceed with the Phase 3 segment of the program.
Amylyx's Focus on Future Developments
Despite this setback, Amylyx remains committed to its research pipeline. The company is prioritizing the pivotal Phase 3 LUCIDITY trial for avexitide, an investigational drug expected to wrap up enrollment by 2025, with topline results anticipated in the first half of 2026.
Continuing Research in Other Areas
Amylyx is also developing AMX0035 for other conditions, including Wolfram syndrome, and advancing AMX0114 in the context of amyotrophic lateral sclerosis (ALS). Expect early data from the Phase 1 LUMINA trial in 2025.
Insights from Recent Analyses
Earlier in the year, the company provided new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide. Notably, a daily dose of 90 mg of avexitide showcased a substantial 64% reduction in moderate to severe hypoglycemic events, a promising statistic for future trials.
Financial Outlook
Amylyx has indicated that they expect their cash resources to be adequate through the end of 2026. This financial stability is crucial as they navigate through their research and development phases.
Recent Developments in ALS Treatments
In March of a recent year, Amylyx reported topline findings from the PHOENIX Phase 3 trial for AMX0035, known as Relyvrio in the U.S. and Albrioza in Canada, aimed at treating ALS. However, the results did not meet the critical endpoint for statistical significance.
Current Stock Performance
As of the latest trading session, AMLX stock was observed to be down by 0.66%, trading at approximately $9.10. Investors may be keeping a close watch on how the company pivots following these developments.
Frequently Asked Questions
What is the reason for halting the AMX0035 program?
The AMX0035 program was discontinued due to a lack of significant efficacy in the trial, showing no notable differences when compared to a placebo.
What other treatments is Amylyx focusing on?
Amylyx is focusing on the Phase 3 LUCIDITY trial of avexitide and continuing development of AMX0035 for Wolfram syndrome and AMX0114 for ALS.
When can we expect results from the avexitide trial?
The topline data from the avexitide trial is expected in the first half of 2026.
How does PSP affect individuals?
PSP adversely affects balance, movement, eye coordination, speech, swallowing, mood, and mental faculties, severely impacting quality of life.
What is the current stock price of AMLX?
As of the latest update, AMLX stock is trading around $9.10, reflecting a minor decline.
